Integra LifeSciences introduces advanced orthobiologics for extremity reconstruction
Integra LifeSciences Holdings Corporation announced in a press release the launch of Trel-XPress Demineralized Bone Matrix, expanding the companys portfolio of bone grafting substitutes for the orthopedic extremity reconstruction surgeon.
Trel-XPress Demineralized Bone Matrix is powered by Accell technology and is composed of a blend of particulate demineralized bone matrix (DBM), Integras proprietary Accell Bone Matrix (ABM) and a reverse phase medium poloxamer. According to an Integra LifeSciences press release, ABM is an open-structured and more dispersed form of DBM, providing a high surface area environment that encourages bone formation.
Integra offers one of the most comprehensive orthobiologics portfolios for the extremity reconstructive surgeon, and the introduction of Trel-XPress Demineralized Bone Matrix reinforces our commitment to give surgeons more solutions for their patients, Robert Paltridge, president of Integra Extremity Reconstruction, stated in the press release.
Trel-XPress Demineralized Bone Matrix offers an alternative for use as a bone graft in orthopedic extremity reconstruction surgeries, according to the press release. It may reduce the need to harvest the patients own bone, sparing the patient additional surgery and limiting the risk of any associated complications.
Trel-XPress Demineralized Bone Matrix will be sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.